Advances and Prospects in Cancer Immunotherapy
Author(s) -
Juhua Zhou
Publication year - 2014
Publication title -
new journal of science
Language(s) - English
Resource type - Journals
eISSN - 2356-7740
pISSN - 2090-8520
DOI - 10.1155/2014/745808
Subject(s) - medicine , immunotherapy , cancer , adoptive cell transfer , cancer immunotherapy , melanoma , immunology , chimeric antigen receptor , cancer research , cancer vaccine , lung cancer , breast cancer , antigen , oncology , t cell , immune system
Cancer immunotherapy is a promising and effective treatment modality for patients with cancers. Cytokine, anticytokine, and antibody therapies appear to be effective in treating various forms of cancer. The human papillomavirus vaccine is protective for cervical cancer, and this discovery has paved the way to the development of cancer vaccines for other forms of virus-associated cancers such as liver cancer and Merkel cell carcinoma. Clinical trials have demonstrated that adoptive cell therapy using tumor-infiltrating lymphocytes can induce tumor regression in approximately 75% of metastatic melanoma patients, suggesting the possibility of using similar technique to effectively treat breast, lung, and renal cancers in the near future. Besides, genetically engineered T cells transduced with genes encoding specific T cell receptors and chimeric antigen receptors have been shown effective in the treatment of cancer patients. These studies suggest that combination therapies are superior choices in cancer immunotherapy for patients
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom